On May, 11 ADMA Biologics, Inc. (ADMA) Analysts See $-0.27 EPS

April 17, 2018 - By Nellie Rakes

ADMA Biologics, Inc. (NASDAQ:ADMA) Corporate Logo
During Q4 2017 the big money sentiment increased to 3. That’s change of 1.86, from 2017Q3’s 1.14. 4 investors sold all, 2 reduced holdings as ADMA Biologics, Inc. ratio increased. 10 grew positions while 8 funds took positions. Funds hold 15.53 million shares thus 121.29% more from 2017Q3’s 7.02 million shares.
Millennium Management Ltd Co has 67,533 shs. Fmr Limited Company has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA). Blackrock owns 25,421 shs. Northern Tru stated it has 0% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). Consonance Capital Mgmt Lp invested in 0.98% or 3.37 million shs. Highbridge Cap Mgmt Limited Liability Corp accumulated 0.02% or 312,500 shs. Advisory Services Network Limited Company owns 700 shs or 0% of their US capital. 3,702 were accumulated by Royal National Bank & Trust Of Canada. Perceptive Advsr Ltd Co holds 3.82 million shs or 0.41% of its capital. Aisling invested 2.29% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). Goldman Sachs Inc accumulated 0% or 30,520 shs. Morgan Stanley holds 3,774 shs or 0% of its capital. Morgens Waterfall Vintiadis And has 500,000 shs for 1.26% of their capital. 683 Capital Mngmt Llc has invested 0.26% of its capital in ADMA Biologics, Inc. (NASDAQ:ADMA). Geode Capital Mngmt Limited Company invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA).

Investors expect ADMA Biologics, Inc. (NASDAQ:ADMA)’s quarterly earnings on May, 11., Faxor reports. Analysts forecast $-0.27 earnings per share. That’s $0.24 up or 47.06 % from 2017’s earnings of $-0.51. Last quarter $-0.24 earnings per share was reported. Analysts predicts 12.50 % negative EPS growth this quarter. On during the last trading session the stock decreased $0.13 or 2.50%, reaching $5.07.Currently ADMA Biologics, Inc. is uptrending after 0.20% change in last April 17, 2017. ADMA has also 62,415 shares volume. The stock underperformed the S&P 500 by 11.35%.

ADMA Biologics, Inc., a biopharmaceutical company, develops, makes, and markets specialty plasma biologics for the treatment of immune deficiencies and infectious diseases.The firm is valued at $229.76 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease.Currently it has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: